Zobrazeno 1 - 10
of 422
pro vyhledávání: '"Jin‐Yuan Shih"'
Autor:
Jin-Yuan Shih, Yung-Hung Luo, Gee-Chen Chang, John Wen-Cheng Chang, Chin-Chou Wang, Tsung-Ying Yang, Wei-Tse Fang, Wen-Yi Shau
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 8, Pp 875-881 (2024)
Background: Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC). In a global phase II study, patients who experience disease progression
Externí odkaz:
https://doaj.org/article/a761d4469e6046f0991578a068010259
Autor:
Meng-Rui Lee, Mu-Hsiang Kao, Ya-Chu Hsieh, Min Sun, Kea-Tiong Tang, Jann-Yuan Wang, Chao-Chi Ho, Jin-Yuan Shih, Chong-Jen Yu
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Although electronic nose (eNose) has been intensively investigated for diagnosing lung cancer, cross-site validation remains a major obstacle to be overcome and no studies have yet been performed. Methods Patients with lung cancer
Externí odkaz:
https://doaj.org/article/b284c56f02204e8d996ff755ccecdb70
Autor:
Shang-Gin Wu, Tzu-Hua Chang, Meng-Feng Tsai, Yi-Nan Liu, Yen-Lin Huang, Chia-Lang Hsu, Han-Nian Jheng, Jin-Yuan Shih
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 1, Pp 102091- (2024)
Osimertinib is an effective treatment option for patients with advanced non-small cell lung cancer (NSCLC) with EGFR activation or T790M resistance mutations; however, acquired resistance to osimertinib can still develop. This study explored novel mi
Externí odkaz:
https://doaj.org/article/0fe9a2a3fca74c738931950645a3cfe1
Autor:
Sheng‐Kai Liang, Chang‐Wei Wu, Ching‐I Chang, Li‐Ta Keng, Meng‐Rui Lee, Jann‐Yuan Wang, Jen‐Chung Ko, Wei‐Yu Liao, Kuan‐Yu Chen, Chao‐Chi Ho, Jin‐Yuan Shih, Chong‐Jen Yu
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17993-18004 (2023)
Abstract Background Studies comparing the effectiveness of either adjuvant oral uracil‐tegafur (UFT) or intravenous chemotherapy on early‐stage (stage I and II) non‐small cell lung cancer (NSCLC) patients treated with complete surgical treatmen
Externí odkaz:
https://doaj.org/article/3f2701feaedf481b8079997fa3acf499
Autor:
Yi-Ling Chen, Yi-Nan Liu, Yen-Ting Lin, Meng-Feng Tsai, Shang-Gin Wu, Tzu-Hua Chang, Chia-Lang Hsu, Huey-Dong Wu, Jin-Yuan Shih
Publikováno v:
Journal of Biomedical Science, Vol 30, Iss 1, Pp 1-20 (2023)
Abstract Background Metastasis is a multistep process involving the migration and invasion of cancer cells and is a hallmark of cancer malignancy. Long non-coding RNAs (lncRNAs) play critical roles in the regulation of metastasis. This study aims to
Externí odkaz:
https://doaj.org/article/67e69c5d45e84907929dff4d4ef66aef
Publikováno v:
Journal of the Formosan Medical Association, Vol 122, Iss 8, Pp 731-737 (2023)
Background: Among the histologic types of lung cancer, adenocarcinoma is the most common. Moreover, lung adenocarcinoma with neuroendocrine differentiation (LANED) is a rare histologic character. So far, the clinical significance remains unclear. Mat
Externí odkaz:
https://doaj.org/article/5988e4797b314cbc8f292ac890dc5e70
Autor:
Tzu‐Hsiu Tsai, Chien‐Hung Gow, Yi‐Nan Liu, Meng‐Feng Tsai, Tzu‐Hua Chang, Shang‐Gin Wu, Min‐Shu Hsieh, Kang‐Yi Su, Jin‐Yuan Shih
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14511-14525 (2023)
Abstract Objective In lung cancer patients, most deaths are caused by the distant dissemination of cancer cells. Epithelial–mesenchymal transition (EMT) and collective cell migration are distinct and important mechanisms involved in cancer invasion
Externí odkaz:
https://doaj.org/article/58e8d9efbdcb48779cafeca430fe60a8
Autor:
Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100624- (2024)
Introduction: EGFR gene mutations are drivers of NSCLC. The RELAY double-blind, placebo (PBO)-controlled phase 3 study revealed superior progression-free survival (PFS) for ramucirumab plus erlotinib (RAM + ERL) versus PBO (PBO + ERL) in patients wit
Externí odkaz:
https://doaj.org/article/5159d19b07b0438c8a46366db7862e0c
Autor:
Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, Heng-Sheng Chao, Cheng-Ta Yang, Chien-Chung Lin, Jen-Yu Hung, Sheng-Yen Hsiao, Chin-Chou Wang, Chih-Feng Chian, Te-Chun Hsia, Yuh-Min Chen
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0303046 (2024)
Osimertinib has demonstrated efficacy in patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) in clinical trials. However, real-world data on its effectiveness remain scarce. Taiwanese patients with
Externí odkaz:
https://doaj.org/article/91e401521dec4d66b6ca2b8d34fd01f0
Autor:
Man-San Zhang, Yi-Chen Yeh, Hsien-Neng Huang, Long-Wei Lin, Yen-Lin Huang, Lei-Chi Wang, Lai-Jin Yao, Tze-Chun Hung, Yu-Fen Tseng, Yi-Hsuan Lee, Wei-Yu Liao, Jin-Yuan Shih, Min-Shu Hsieh
Publikováno v:
PLoS ONE, Vol 19, Iss 4, p e0301120 (2024)
Determining the exact type of epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation in lung cancer has become important. We found that not all ex20ins mutations reported by cobas EGFR test v2 could be validated by Sanger sequen
Externí odkaz:
https://doaj.org/article/17f718bdd88b4b328a4f85673a79643c